|
Market Data
Bio-Techne Corporation
Bio-Techne Corporation is a global provider of life science reagents, instruments, and services, serving the research, diagnostics, and bioprocessing sectors. The company's core business is split into two segments: Protein Sciences, which offers a diverse portfolio of biological reagents and analytical tools for protein analysis, and Diagnostics and Spatial Biology, which focuses on developing diagnostic products and assays. Bio-Techne's Protein Sciences segment provides critical tools for cell and gene therapy, while its Diagnostics segment develops products for regulated diagnostics and advanced tissue analysis. The company's offerings support a variety of applications, from basic research to clinical diagnostics, positioning Bio-Techne as a key supplier in the expanding life sciences market. Founded in 1976 and headquartered in Minneapolis, Minnesota, Bio-Techne has evolved to meet the evolving needs of the scientific community.
TECH is currently trading at $59.25, giving Bio-Techne Corporation a market cap of 9.27B and a P/E ratio of 115.8. Today's range spans $59.25–$59.25, with shares opening at $59.25 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 50/100.
Over the past year TECH has traded between $46.01 and $72.16 - the current price is +28.8% off the 52-week low and -17.9% from the high. 25 analysts cover the stock with a Buy consensus and a mean 12-month target of $72.27 (range $54.00–$80.00), implying upside of +22.0%.
Bio-Techne Corporation (TECH) sits at the intersection of bullish technical momentum and neutral sentiment (50/100) - score 68/100 (BUY), price $59.25 (in the middle of its 52-week range). (P/E: 115.8) At 9.27B in Healthcare market cap, the limited float means that conviction buying from a concentrated set of investors can drive the price through key levels quickly. Annual range: $46.01–$72.16. That asymmetry is what makes small-cap setups like this worth monitoring.
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.53 | - | - |
| Q2'26 | $0.54 | $0.46 | -14.5% |
| Q3'25 | $0.42 | $0.42 | -0.4% |
| Q2'25 | $0.50 | $0.53 | +5.8% |
| Q1'25 | $0.51 | $0.56 | +10.4% |
| Q4'24 | $0.39 | $0.42 | +7.8% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $316M | - | - |
| Q2'26 | $317M | $296M | -6.5% |
| Q3'25 | - | $287M | - |
| Q2'25 | - | $317M | - |
| Q1'25 | - | $316M | - |
| Q4'24 | - | $297M | - |
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).